Lung
|
MK-7684A-006
Open-label phase 3 study of MK-7684A (vibostolimab with pembrolizumab) in combination with concurrent chemoradiotherapy followed by MK-7684A versus concurrent chemoradiotherapy followed by durvalumab in participants with unresectable, locally advanced, stage III NSCLC.
|
Recruitment open
|
SPARTA
Phase 1/2 multicentre study of the safety, pharmacokinetics, and preliminary efficacy of APL-101 in subjects with non-small cell lung cancer with c-Met EXON 14 skip mutations.
|
Recruitment open
|
TROG 20.01 – CHEST RT
A phase 2 study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer (SCLC).
|
Recruitment open
|
eVOLVE-Lung02
A phase 3, two-arm, parallel, randomised, multi-centre, open-label, global study to determine the efficacy of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC).
|
Recruitment open
|
MoST 8
Single-arm, open-label, signal-seeking phase 2a trial of the activity of trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations.
|
Recruitment open
|
OCEANiC
A phase 2, open-label, multi-centre clinical trial of osimertinib with or without adjuvant chemotherapy guided by tumour NGS co-mutation status and ctDNA detection in patients with stage IIA-IIIA EGFR-mutant non-small cell lung cancer following complete surgical resection.
|
Recruitment open
|
R3767-ONC-2236
A randomised, double-blind phase 2/3 study of fianlimab (anti-LAG-3 antibody), cemiplimab (anti-PD-1 antibody), and chemotherapy versus cemiplimab and chemotherapy in first-line treatment of patients with advanced NSCLC irrespective of PD-L1 expression levels.
|
Recruitment open
|
SUNRAY-01
A global pivotal study in patients with KRAS G12C-mutant, locally advanced or metastatic non-small cell lung cancer, comparing first-line treatment of pembrolizumab + LY3537982 vs pembrolizumab + placebo in those with PD-L1 ≥50%, or pembrolizumab, pemetrexed, platinum chemotherapy + LY3537982 vs pembrolizumab, pemetrexed, platinum chemotherapy + placebo regardless of PD-L1 expression.
|
Recruitment open |
V940-002
A phase 3, randomized, double-blind, placebo- and active comparator-controlled clinical study of adjuvant V940 (mRNA-4157) + pembrolizumab vs adjuvant placebo + pembrolizumab in participants with resected Stage II-IIIB (N2) non-small-cell lung cancer.
|
Recruitment open |
Breast
|
CELC-G-301
A phase 3, open-label, randomised, two-part study comparing gedatolisib in combination with palbociclib and fulvestrant to standard-of-care therapies in patients with HR-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor in combination with non-steroidal aromatase inhibitor therapy.
|
Recruitment open
|
EMBER-4
A randomised, open-label, phase 3 study of adjuvant imlunestrant vs standard adjuvant endocrine therapy in patients who have previously received 2 to 5 years of adjuvant endocrine therapy for ER-positive, HER2-negative early breast cancer with an increased risk of recurrence.
|
Recruitment open
|
EXPERT
Randomised phase 3 trial of adjuvant radiotherapy versus observation following breast-conserving surgery and endocrine therapy in patients with molecularly characterised luminal A early breast cancer.
|
Recruitment open
|
GS-US-586-6144
A phase 2, randomised, open-label study evaluating the safety and efficacy of magrolimab in combination with nab-paclitaxel or paclitaxel versus nab-paclitaxel or paclitaxel in previously untreated patients with metastatic triple-negative breast cancer.
|
Recruitment closed
|
OPTIMA
Optimal personalised treatment of early breast cancer using multiparameter analysis.
|
Recruitment open
|
Head & Neck
|
BNT113-01 (AHEAD-MERIT)
An open-label, phase 2, randomised trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first-line therapy in patients with unresectable recurrent, or metastatic head & neck squamous cell carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1.
|
Recruitment open
|
Skin
|
C-POST
A randomised, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma.
|
Recruitment open
|
Upper GI
|
PALEO
Phase 2 clinical trial of chemoradioimmunotherapy for the alleviation of oesophageal cancer complications.
|
Recruitment open
|
ProvIDHe
An open-label, early access, phase 3b study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma.
|
Recruitment open
|
ZAP
A phase 2, open-label study to assess the antitumour activity and safety of zolbetuximab (IMAB362) in combination with chemotherapy as first-line treatment in metastatic pancreatic adenocarcinoma.
|
Recruitment open
|
PURPLE
Pancreatic cancer: understanding routine practice & lifting end results (PURPLE). A prospective pancreatic cancer clinical registry.
|
Recruitment open
|
Lower GI
|
MOUNTAINEER-03
An open-label, randomised, phase 3 study of tucatinib in combination with trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either cetuximab or bevacizumab as first-line treatment for subjects with HER2+ metastatic colorectal cancer.
|
Recruitment open
|
ALT-TRACC
Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A treatment of recurrent and advanced colorectal cancer registry-based prospective randomised trial.
|
Recruitment open
|
TRACC-SELECT
Treatment of Australian colorectal cancer – selecting biomarkers of interest registry.
|
Recruitment open
|
Solid Tumours
|
|
|
|
CA052-002
A phase 1/2 study of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumours.
|
Recruitment open
|
CF33-hNIS-002
A phase 1, dose-escalation safety and tolerability study of VAXINIA (CF33-hNIS), administered intratumorally or intravenously as a monotherapy or in combination with pembrolizumab in adult patients with metastatic or advanced solid tumors (MAST).
|
Recruitment open
|
AT-0174-001
A phase I study to evaluate the safety, tolerability, pharmacology, and preliminary efficacy of AT-0174 in subjects with advanced solid malignancies.
|
Recruitment open |
Brain
|
BRAIN registry
Brain registry Australia: Innovation and translation (BRAIN)
|
Recruitment open
|
LUMOS2
Low & anaplastic grade glioma umbrella study of molecular guided therapies.
|
Recruitment open
|
Other
|
IMPARP-HRD
An open-label, signal-seeking, translational phase 2 trial of pamiparib in combination with tislelizumab in patients with advanced tumours with homologous recombination repair defects.
|
Recruitment open
|
KEYNOTE-587
A multicentre, open-label, phase 3 extension trial to study the long-term safety and efficacy in participants with advanced tumours who are currently on treatment or in follow-up in a pembrolizumab trial.
|
Recruitment open
|